SLC5A2 and chronic kidney disease: Female gender was independently associated with a lower rate of SGLT2 inhibitor use among patients with type diabetes and a diagnosis of HFrEF (aOR, 0.83; 95% CI, 0.75-0.92), ASCVD (aOR, 0.83; 95% CI, 0.81-0.85), or CKD (aOR, 0.85; 95% CI, 0.81-0.90).